当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-Feb-01 , DOI: 10.1016/s1470-2045(17)30911-7
Kim N Chi , Andrew Protheroe , Alfredo Rodríguez-Antolín , Gaetano Facchini , Henrik Suttman , Nobuaki Matsubara , Zhangqun Ye , Bhumsuk Keam , Ronaldo Damião , Tracy Li , Kelly McQuarrie , Bin Jia , Peter De Porre , Jason Martin , Mary B Todd , Karim Fizazi

In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study.

中文翻译:

醋酸阿比特龙加泼尼松联合雄激素剥夺治疗后,新近诊断为转移性去势初治前列腺癌(LATITUDE)的患者的患者报告结局:一项国际随机的,3期临床试验。

在LATITUDE试验中,与安慰剂加ADT相比,初诊断为高风险,未进行去势的前列腺癌患者,在雄激素剥夺治疗(ADT)中加入醋酸阿比特龙加泼尼松可以改善总体生存率。了解治疗对患者报告的结局(PROs)和与健康相关的生活质量(HRQOL)的影响对于治疗决策很重要;因此,在LATITUDE研究中,我们旨在分析ADT加醋酸阿比特龙酯和泼尼松与ADT加安慰剂对PROs和HRQOL的影响。
更新日期:2018-02-01
down
wechat
bug